drugset / Trial / NCT05382208
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Phase 2
Active not recruiting
133 enrolled
Weill Medical College of Cornell University
National Heart, Lung, and Blood Institute (NHLBI) · collabUniversity of California, Los Angeles · collabUniversity of Iowa · collabUniversity of Michigan · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections.
Timeline
- Start
- 2022-08-22
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 100 mg | Oral |